CHOP is the most commonly used chemotherapy regimen in the first line treatment of PTCL and brentuximab vedotin (BV)‐CHP is now used to treat CD30‐positive PTCL.10 This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.